Metabolomics of blood reveals age-dependent pathways in Parkinson’s Disease

Nicola D’Ascenzo1,2*, Emanuele Antonecchia1,2, Antonella Angiolillo3*, Victor Bender2, Marco Camerlenghi4, Qingguo Xie1,2,5* and Alfonso Di Costanzo3

Abstract
Background: Parkinson’s Disease (PD) is the second most frequent degenerative disorder, the risk of which increases with age. A preclinical PD diagnostic test does not exist. We identify PD blood metabolites and metabolic pathways significantly correlated with age to develop personalized age-dependent PD blood biomarkers.

Results: We found 33 metabolites producing a receiver operating characteristic (ROC) area under the curve (AUC) value of 97%. PCA revealed that they belong to three pathways with distinct age-dependent behavior: glycine, threonine and serine metabolism correlates with age only in PD patients; unsaturated fatty acids biosynthesis correlates with age only in a healthy control group; and, finally, tryptophan metabolism characterizes PD but does not correlate with age.

Conclusions: The targeted analysis of the blood metabolome proposed in this paper allowed to find specific age-related metabolites and metabolic pathways. The model offers a promising set of blood biomarkers for a personalized age-dependent approach to the early PD diagnosis.

Keywords: Parkinson’s Disease, Metabolomics, Age, Biomarkers

Background
Parkinson’s disease (PD) is the second most frequent neurodegenerative disorder. The Global Burden of Disease Study estimates the prevalence of PD to be approximately 6.2 million people worldwide, with a prediction of nearly 13 million by 2040 [1]. Although the connection between the accumulation of α-synuclein and the PD pathology has been extensively studied [2], the multiple mechanisms contributing to its pathogenesis, including protein misfolding and aggregation, mitochondrial injury, oxidative stress and inflammation, are not fully understood yet. As a result, a PD diagnosis is only possible after the insurgence of mobility functions impairment, such as the well-known tremor, following a consistent loss of dopaminergic neurons in the substantia nigra and in the striatum. However, at sub-clinical stage, PD is accompanied by a non-specific symptomatology including depression, sleep disturbance, or loss of olfactory sense, which most often remain unaddressed, due to the absence of a subclinical diagnostic PD test [3, 4].

The understanding of the relationship between PD and age has the potential to play a significant role in the personalized early PD diagnosis [5]. Sub-clinical PD manifestation occurs early, up to 20 years before the first clinical symptoms, with a risk increasing with age. This suggests that a series of age-related disfunctions may contribute to the development of PD. Proteins accumulation, genetic factors, autophagy, mitophagy, and lower protection against oxidative stress have been proposed as possible age-related PD factors [6–9].
Against this background, the blood metabolome contains a rich source of information. In fact, the metabolic pathways affected by PD originate metabolites, which are released in the blood stream. The concentration of a series of amino acids, fatty acids, acylcarnitine, lipids, purines, organic acids, and sugars revealed PD-related dysfunctions of the metabolism of branched chain amino acids, tryptophan, lipid, energy, and purine, and of oxidative stress/redox homeostasis metabolic pathway [10]. Blood metabolome reflects in-vivo physiological states influenced by genetics, epigenetics and lifestyle and is therefore intimately connected with the biological age. It has been found that antioxidants, nitrogen and muscle- or kidney-related elements indicate characteristic age-related accumulation and deficiencies of metabolites [11]. Although PD is an age-related neurodegenerative disorder [12], an evidence of age-related PD significant metabolite disorder has not been found until now. Besides blood, metabolites contained in saliva, cerebrospinal fluid (CSF) and sebum have been investigated. Although a series of metabolic pathways such as carnitine shuttle, valine, leucine and isoleucine degradation, fatty acid biosynthesis, sphingolipid, arachidonic acid, primary bile acids, fatty acids, ether lipids and vitamin E metabolism have been identified as possible metabolic pathways deeply related with PD, no significant correlation between the involved metabolites, PD diagnosis and age was observed [10, 13–16].

The main aim of this paper was to study a possible relationship between PD and age by identifying blood metabolites, which express a significant age-dependent pattern in PD. This would allow to develop personalized age-dependent biomarkers. We used a supervised machine learning approach to find novel blood PD biomarkers by comparing the blood metabolome of PD and healthy subjects. We further applied a statistical analysis based on unsupervised machine learning and Bonferroni correction to discover possible age correlations of the selected biomarkers. We finally applied an enrichment pathway analysis to the selected biomarkers to identify the metabolic pathways related to age, either in PD or in healthy patients.

**Methods**

**Sample participants**

The subjects included in this study were consecutively enrolled at the Centre for Research and Training in Medicine of Aging of the University of Molise. We recruited 39 patients affected by PD and 39 healthy controls (HC). The subjects followed the same Mediterranean alimentation, without any specific dietary requirement. The demographic and clinical characteristics of the two groups are described in Table 1. PD patients were included in the study if the following conditions were verified:

1. A “clinically established” diagnosis of PD according to the criteria published by the Movement Disorder Society (MDS) [17]
2. Mini Mental State Examination (MMSE) score higher than or equal to 24;
3. Clinical Dementia Rating (CDR) scale score lower than or equal to 6;
4. Treatment with L-DOPA for at least 3 months.

We assessed the degree of PD severity with the MDS-revised Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) and the Hoehn and Yahr scale [18]. The study was conducted in accordance with the ethical principles stated in the Declaration of Helsinki, and with approved national and international guidelines for human research. The Institutional Review Board (IRB) of the University of Molise reviewed and approved the study (IRB Prot. n. 17/2020). A written informed consent was obtained from each participant.

**Sample collection**

The blood sampling was performed between 8:00 and 8:30 a.m. after an overnight fasting of at least 8–10 h. Antecubital venous blood was collected in vacutainer tubes for plasma preparation (Becton & Dickinson, Milan, Italy).

**Table 1** Description of the participants included in the statistical analysis

| Parameter               | HC         | PD         |
|-------------------------|------------|------------|
| Age (years)             | 73 ± 7.1   | 71 ± 6.4   |
| Gender (Male/Female)    | 27/12      | 27/12      |
| Scholarity              | 12.1 ± 3.9 | 11.02 ± 4.1|
| MMSE                    | 28.5 ± 2.4 | 25.4 ± 2.3 |
| UPDRS                   | 55.3 ± 24.4|            |
| Hoehn and Yahr score    | 2.5 ± 2.4  | 4.7 ± 3.0  |
| GDS                     | 26.3 ± 2.0 | 26.5 ± 2.3 |
| Alcohol                 | 62%        | 30%        |
| Hypertension            | 41%        | 42%        |
| Diabetes                | 13%        | 15%        |
| Dyslipidemia            | 45%        | 32%        |
| TIA/stroke              | 3%         | 12%        |
| Myocardial infarction   | 5%         | 9%         |
| Antihypertensive drugs  | 42%        | 46%        |
| Hypolipidemic drugs     | 13%        | 11%        |
| Lipid-lowering drugs    | 44%        | 22%        |
| Antiplatelet drugs      | 11%        | 22%        |
and immediately centrifuged to obtain plasma samples, which were stored at -80 °C until shipment to the analytical laboratory of BIOCRATES Life Sciences AG. The metabolomic approach based on mass spectrometry was used to obtain a quantitative determination of 630 endogenous metabolites, grouped in different biochemical classes for each plasma sample (MxP® Quant 500 kit). All pre-analytical and analytical procedures related to this project were performed, documented, and reviewed according to BIOCRATES Life Sciences AG's ISO 9001:2015 certified quality management guidelines and standards. We used the MxP® Quant 500 kit (Biocrates) for the quantification of several endogenous metabolites of various biochemical classes. Lipids and hexoses were measured by flow injection tandem mass spectrometry (FIA-MS/MS) analysis using a QTRAP® 5500 instrument (AB Sciex, Darmstadt, Germany) with an electrospray ionization (ESI) source. Other metabolites were measured by liquid chromatography coupled to tandem mass spectrometry (LC–MS/MS) also using the QTRAP® 5500 Instrument. A summary of the 630 metabolites measured for this study is reported in the Additional file 1: Table S1. We removed dyhydroxy-phenilalanine and tyrosine from the list of metabolites as they were clearly related to the specific therapy of PD patients.

Statistical analysis

We pre-processed the metabolomic dataset, by reducing each variable to zero average and unitary variance. We compared two approaches for the assessment of the variation of the metabolome between the two groups of subjects. Partial least squares-discriminant analysis (PLS-DA) is a regression technique for modeling the relationship between the metabolomic data block and the respective labeled categories (PD = +1; HC = −1) by maximizing their covariance [19]. The PLS algorithm reduces the input metabolomic data to nplg independent components and a regression coefficient matrix is used to predict the labels [20]. We compared the PLS-DA model with the orthogonal projections to latent structures (OPLS) approach [21], which provides a higher level of sophistication. It separates in fact the metabolomic dataset in two different parts. The first one consists of nplg predictive components, which are correlated with the expected categories. The second one consists of a nort-dimensional orthogonal non-predictive block, which is generated by the intrinsic variability of the samples and is not correlated with the expected categories. We estimated the number of optimal components by performing permutation tests for regression metrics and two-tailed permutation tests for each metabolite relative to its loading. We calculated the P-value of the PLS-DA and OPLS models by using a resampling with replacement (bootstrapping) validation technique. It is known that the higher is the number of components used to model the metabolomic dataset, the higher will be the probability of overfitting. We adopted a K-fold cross-validation method by comparing the goodness of fit R²Y and the predictability Q² parameters after a random variation of the labels [22]. If the R²Y parameter after permutations is systematically higher than in the case of the correct data, then the model exhibits an illogic overfitting ability to predict any random permutation of the labels. Finally, we selected the best predictive model and the number of components avoiding overfitting and we calculated for each metabolomic parameter the variable influence on projection (VIP). However, the use of VIP values in the context of the selection of significant parameters needs a dedicated validation. There are in fact two problems. The first one is related to the intrinsic statistical fluctuations of the VIP value itself. Although the R²Y and Q² parameters are calculated above by random label permutation and bootstrapping, that is not enough to prevent random fluctuations of the VIPs due to the highly variable nature of the data. There is therefore a certain probability that repeating the same test with an independent dataset may provide significantly different VIP values. This is particularly true in OPLS models, which, as mentioned above, aim at separating the systematic variation contained in the data into two parts—a predictive part that is correlated to the labels and an orthogonal part that is uncorrelated to the labels. A second problem, related to the first one, is the number of subjects in the study, which reflects to the statistical significance of the findings. To address this issue, we followed a four-steps procedure:

1) Model validation we randomly selected 80% of the entire dataset to compose a training sample. As mentioned above, we performed a permutation test for regression metrics, and a two-tailed permutation test for each variable to its loading (L). VIP values are selected with P < 0.05 and |L| > 0.04. We performed the receiver operating characteristics (ROC) analysis based on the selected parameters and we estimated the 95% confidence interval of the area under the curve (AUC) by using a resample with replacing (bootstrapping) approach.

2) VIP values validation we calculated the VIP values of the selected parameters repeating the model training 1000 times. We used a resample with replacing (bootstrapping) approach by randomly sampling 80% of the entire dataset at each evaluation. We selected only these parameters which exhibit a VIP > 1.0 in more than 95% of the trials. This test allows to remove parameters which are mostly affected by statistical fluctuations.
VIP values reduction following [23], we further strengthened the selection of the significant parameters by applying a features reduction strategy based on the principal components analysis (PCA). We analyzed the group of parameters selected at step (2) and we identified the number $N_{\text{pca}}$ of independent principal components $f_i$ accounting for 80% of the total variance. We extracted the metabolites with the most important contribution to each $f_i$, identified as the ones with PCA coefficient $|c_j| > 0.9\max |c_j|$. 

Metabolites selection We finally selected as significant only the metabolites which have both a validated VIP in step (2) and a significant PCA coefficient in step (3).

Age dependence
We calculated the correlation between the principal components $f_i$ and the age of the patients by using a Spearman correlation statistical method. We selected only those significant principal components exhibiting a correlation coefficient $|r|>0.5$ ($P < 0.05/N_{\text{pca}}$). We applied a Bonferroni correction taking into account the multiple comparisons between independent statistical tests [24–29]. We finally verified that the metabolites selected in (4) also exhibit an age correlation in correspondence to the principal component in which they have a significant contribution. Data and software have been included in RADIOLYTX (www.radiolytx.com) and in the HPE Ezmeral platform (www.hpe.com/us/en/software.html).

Pathway analysis
We performed an enrichment analysis with the software MetaboAnalyst (Version 4.0). Significant features were mapped into the Kyoto Encyclopaedia of Genes and Genomes (KEGG). Feature hits on known metabolite networks were tested against a null distribution produced from permutations to yield significance values of metabolites enriched within any given network [30]. We performed first the enrichment analysis on the entire set of selected and validated metabolites with VIP $>1.0$. At a second step, we restricted the analysis to these principal components $f_i$ exhibiting a significant age dependence. We extracted the metabolites with the most important contribution to each $f_i$, identified as the ones with PCA coefficient $|c_j| > 0.9\max |c_j|$. We applied the enrichment analysis to each group of significant metabolites characterizing each component $f_i$, and we identified possible age-dependent metabolic pathways for PD.

Results
Analysis of patient metadata
An overview of the clinical and demographic data of the patients is reported in Table 1. Two tailed t-test did not reveal any significant difference in age and BMI between PD patients and HC ($P = 0.054$ and $P = 0.194$, respectively). The Mini Mental State Examination (MMSE) score was found slightly significantly lower in PD group ($P = 0.047$). The ratio between men and women was 2:1 in the PD group, confirming the male prevalence of the disease reported in previous studies [31]. We selected a HC group with the same composition to avoid bias. Other indicators, such as smoke, scholarity, alcohol consumption, hypertension, diabetes, and dyslipidemia are not found significantly related to PD.

Data driven prediction of PD
We reported the scores plot of the first two components of a PLS-DA model with $n_{\text{pls}} = 3$ in Fig. 1A. The PD patients and HC subjects appeared well separated. The model had an acceptable $R^2_Y = 0.76$, but a very poor $Q^2 = 0.06$. A resampling with validation replacement technique ($n=500$) confirmed that the model described the metabolomic data with a P-value of 0.02 (Fig. 1B). The reason of such a poor predictability was due to a sizable overfitting. As shown in Fig. 1C, a random permutation of the label vectors did not affect the goodness of the fit and the $R^2_Y$ value. We verified that lowering the number of components did not improve the performances of the PLS-DA technique. The OPLS model with 3 orthogonal and 1 predictive component exhibited a better performance than PLS-DA, as qualitatively visible in the scores plot (Fig. 1D). Such an excellent disentanglement between PD and HC subjects was confirmed by an $R^2_Y = 0.83$ and a $Q^2 = 0.57$. The model was validated with p-value of $9 \times 10^{-4}$ (Fig. 1E). Finally, the goodness of fit and the $R^2_Y$ values were significantly affected by random permutations of the labels, therefore confirming the absence of overfitting (Fig. 1F). In particular, the smaller was the similarity between the randomly permuted and the original labels, the smaller was the $R^2_Y$. We verified that increasing the number of orthogonal or predictive components would increase the probability of overfitting. We therefore concluded that OPLS with 3

(See figure on next page.)

Fig. 1 Data driven modeling for the discrimination between PD and HC subjects. The PLS model exhibits a good separation between the two categories of subjects (A) and its goodness is apparently confirmed by a resampling with replacement validation technique (B). However, we observe a non-negligible overfitting (C). With respect to PLS, the OPLS model exhibits a better separation between the two classes (D), confirmed with a P-value of $9 \times 10^{-4}$ (E) and absence of overfitting (F).
Fig. 1 (See legend on previous page.)
orthogonal and 1 predictive component was the best suited model for the metabolomic data considered in this study.

Selection of significant metabolites
The four steps of the parameter selection are shown in Table 2 and in the Additional file 1: Table S2. At a first step, we used the variable importance in projection (VIP) parameter to select those metabolomic parameters playing a significant role in the discrimination between PD and HC group. A total of 320 metabolites exhibited VIP > 1. We performed a receiver operating characteristics (ROC) analysis of this model restricted to these significant parameters (Fig. 2A). The 95% confidence interval of the area under the curve (AUC) was (0.972, 1.0), confirming the excellent discrimination power of the OPLS predictive model.

However, we found that not all the 320 parameters have a significant contribution to the model. A large fraction of these parameters exhibits VIP > 1 only because of statistical fluctuations. As mentioned above, we validated the significance of the parameters using a resample with replacing (bootstrapping) approach by randomly sampling 80% of the entire dataset at each evaluation and repeating the model training 1000 times. Only 76 metabolic parameters, highlighted in Table 2 and Additional file 1: Table S2, exhibited a VIP > 1.0 in more than 95% of the cases.

We performed the final validation of the selected parameters based on an unsupervised Principal Components Analysis (PCA) technique. We found that 80% of the total variance of the selected parameters could be described with five principal components. The significant parameters with PCA coefficient $|c_j| > 0.9\max|c_j|$ are reported in Table 2 and in the Additional file 1: Table S2. The cross-validated parameters, exhibiting a validated VIP > 1 and a significant contribution to a PCA component, are 33 and are highlighted in Table 2 and in the Additional file 1: Table S2. They belong to the groups of acylcarnitines, amino acids, ceramides, cholesteryl esters, dihexosyl ceramides, fatty acids, hexosyl ceramides, lysophosphatidyl- and phosphatidylcholines, sphingomyelins, triglycerides, and vitamins.

Age dependence of metabolites
The principal components identified in the study define three distinct groups in relation to age. The first group is represented by the principal components $f_0$, $f_1$, and $f_4$. Figure 2B shows the scatter plot of the value of $f_1$ versus the age for PD and HC: no significant correlation was observed ($r = 0.08$, $P = 0.96$; $r = 0.02$, $P = 0.98$) for $f_1$. A similar situation was encountered for $f_0$ and $f_4$. The second group, more interestingly, as shown in Fig. 2C, was represented by the component $f_2$ accounting for 21% of the total variance. It exhibited a clear correlation with the age of PD patients ($r = -0.52$, $P = 0.007$) but not of HC ($r = 0.33$, $P = 0.09$). The third group, finally, as shown in Fig. 2D, was represented by the component $f_3$ and accounted for the 11% of the total variance. It exhibited a clear correlation with the age of HC subjects ($r = 0.64$, $P = 5.6 \times 10^{-4}$) but not of PD patients ($r = 0.11$, $P = 0.56$). The main parameters contributing to the linear expansion of the principal components are reported in Table 2. They were identified as the ones with coefficients $|c_j| > 0.9\max|c_j|$. For instance, sphingomyelin C16:0 (Fig. 2E), choline (Fig. 2F), and hexadecanoyl-carnitine (Fig. 2G) were significant examples of the three categories of metabolites.

Pathway analysis and age in PD
We performed pathway enrichment analysis to identify the effect of age in the metabolic pathways associated to PD. At a first step we performed the analysis to the entire set of identified significant metabolites, thus neglecting any age dependence. To provide an impression of the variability of the validated parameters used at this first step of the enrichment analysis, we report the box plot of their concentration in Fig. 3A. We notice that, with respect to HC subjects, PD patients have an increased level of ceramides (d18:1/24:1) and (d18:1/26:1), triacylglycerides (18:1/32:3) and (18:2/32:1), phosphatidyl-choline and C34:2, and putrescine. sphingomyelin C22:3 followed an opposite trend, being reduced in PD patients. As reported in Fig. 3B, the enrichment analysis reveals that the biosynthesis of unsaturated fatty acids (P = 0.004), the tryptophan metabolism (P = 0.01) and the glycine, serine and threonine metabolism (P = 0.05) are the main metabolic pathways, which express the significant selected metabolites. To verify the age dependence of these three metabolic pathways, we selected the metabolic parameters which have a significant impact into each principal component. As visible in Table 2, the parameters can be separated into three completely disjoint groups corresponding to $f_1$, $f_2$ and $f_3$, which address age correlation in no subjects, only in PD and only in HC, respectively. We performed a pathway analysis to the three groups distinctly and we found that metabolites not exhibiting any age correlation are associated with tryptophan metabolism. Similarly, metabolites exhibiting age correlation only in HC subjects are associated with the biosynthesis of unsaturated fatty acids. Finally, metabolites exhibiting age correlation only in PD subjects are associated with the glycine, serine and threonine metabolism.
Table 2: Selection of the significant metabolites

| Type                        | Name                                | $f_i$ | C  | Name                               | $f_i$ | C  |
|-----------------------------|-------------------------------------|-------|----|------------------------------------|-------|----|
| Acylcarnitines              | Carnitine                           | 0.9   | 0  | Hexadecanoyl                       | 3     | 0.9* |
|                            | Acetyl-                             | 3     | 0.9*| Hexadecenoyl                       | 3     | 0.8* |
|                            | Butenyl-                            | 1.2   | 0.5*| Octadecenoyl                       | 3     | 0.8* |
|                            | Methylmalonyl                       | 2.4   | 1   | Tetradecenoyl                      | 1.0   | 0.8* |
| Alkaloids                   | Trigonelline                        | 1.1   |    |                                    |       |    |
| Amine oxides                | Trimethylamine N-oxide               | 1.7*  |    |                                    |       |    |
| Amino acid related          | Asymmetric Dimethylargin            | 0.9   | 1.1| Kynurenine                         | 0.8   |    |
|                            | Methionine-sulfoxide                | 2     | 0.8*| 1-Methylhistidine                  | 0.8   |    |
| Amino acids                 | Cysteine                            | 1.2   |    | Glutamine                          | 1.1   | 2.0  |
|                            | Threonine                           | 1.2   |    |                                    |       |    |
| Bile acids                  | Cholic acid                         | 2.0   |    | Chenodeoxy acid                    | 1.9*  | 1.4  |
|                            | Glycolithochol acid*                | 1.4   |    | Deoxycholic acid                   | 1.2*  |    |
| Biogenic Amines             | Gamma-amino butyric acid            | 0.8*  |    | Putrescine                         | 1.6*  | 0.2  |
| Ceramides                   | d16:1/24:0                          | 1.3   | 1.2| d18:1/26:1                         | 1.3   | 1.2  |
|                            | d18:1/16:0                          | 1.1   | 1.2| d18:2/24:0                         | 1.1   | 1.1  |
|                            | d18:1/18:0                          | 1     | 1.2| d18:1/24:1                         | 1.2   | 1.1  |
|                            | d18:0/26:1 OH                       | 10.3  |    |                                    |       |    |
|                            | d18:1/20:0 (OH)                     | 1.2   | 1.2|                                    |       |    |
| Cholesteryl esters          | 16:1                                | 0.9   | 2.0 | 22:1                               | 2.0   | 0.7* |
|                            | 17:1                                | 1.1   | 2.0 | 20:1                               | 2.0   | 0.7* |
|                            | 18:1                                | 1     | 2.0 |                                    |       | 0.7* |
| Cresols                     | p-Cresol sulfate                    | 1.2   |    |                                    |       |    |
| Diglycerides                | 16:1_18:0                           | 0.8   | 2  | 18:2_18:4                          | 0.7   |    |
|                            | 16:0_18:1                           | 0.9   | 2  | 18:1_18:1                          | 0.9   | 2.0  |
|                            | 16:0_20:3                           | 0.8*  | 4.6| 18:2_18:2                          | 1.4*  |    |
| Dihexosyl ceramides         | d18:1/14:0                          | 1.1   | 1.2| d18:0/26:1                         | 1.2   |    |
|                            | d18:1/16:0                          | 1     | 1.2| d18:1/24:0                         | 1.1   |    |
|                            | d18:1/18:0                          | 1     | 1.2| d18:1/24:1                         | 1.1   |    |
| Fatty acids                 | Arachnidonic                        | 2     | 0.6*| Docosahex                          | 3     | 0.7* |
|                            | Eicosatrienoic                      | 0.3*  |    |                                    |       | 0.2  |
|                            | Octadecadienoate                    | 3     | 0.8*|                                    |       |    |
| Hexosyl ceramides           | d18:1/24:1                          | 1     | 1.2*| d18:1/23:0                         | 1.2   |    |
|                            | d18:1/18:1                          | 1     | 1.1| d18:1/26:0                         | 1.2   |    |
| Hormones                    | Cortisol                            | 1.2*  |    |                                    |       | 0.9  |
| Indoles                     | Indoleacetic acid                   | 1.7*  |    |                                    |       | 0.7  |
| Lyso-phosphatidyl           | LysoPC(17:0)                        | 2     | 1.1*|                                    |       | 0.8* |
| Phosphatidyl-cholines       | aaC34:1                             | 1     | 1.1|                                    |       | 1.1  |
|                            | aaC32:0                             | 1     | 1.1|                                    |       | 1.2  |
|                            | aaC32:2                             | 1.2   | 1.2*|                                    |       | 1.2  |
|                            | aaC34:2                             | 2.1   | 4  |                                    |       | 1.2  |
|                            | aaC44:1                             | 2     | 2   |                                    |       | 1.2  |
| Sphingomyelins              | Hydro-SM(14:1)                      | 0.9   | 1.0*|                                    |       | 0.6  |
|                            | Hydro-SM(16:1)                      | 1     | 0.9|                                    |       | 0.9  |
|                            | Hydro-SM(16:1)                      | 1     | 0.9|                                    |       | 0.9  |
|                            | Hydro-SM(22:1)                      | 1     | 0.9|                                    |       | 0.9  |
|                            | Hydro-SM(22:2)                      | 1     | 0.9|                                    |       | 0.9  |
|                            | Hydro-SM(24:1)                      | 1     | 0.9|                                    |       | 0.9* |
Paper: Metabolic Changes in PD

**Table 2 (continued)**

| Type          | Name                     | f₁       | C     | Name                     | f₁       | C     | Name                     | f₁       | C     |
|---------------|--------------------------|----------|-------|--------------------------|----------|-------|--------------------------|----------|-------|
| Triglycerides | (16:0_35:3)              | 0        | 1.2*  | (18:2_31:0)              | 0        | 1.2*  | (18:2_35:1)              | 0        | 1.3*  |
|               | (d18:1/16:0)             | 1.1*     |       | (d18:1/18:0)             | 1.1*     |       | (d18:1/24:1)             | 1.1*     |       |
|               | (d18:1/26:1)             | 1.1*     |       |                          |          |       |                          |          |       |
| Vitamins      | Choline                  | 2        | 0.8*  |                          |          |       |                          |          |       |

The table contains the association of each element to the respective principal component f₁, f₂, or f₃ (if significant). C indicates the ratio between the concentration of the metabolite in PD and HC; values higher or lower than 1.0 indicates, respectively, elevated or decreased metabolite level in PD. The asterisk (*) indicates parameters validated with OPLS. Parameters in bold are additionally cross-validated with PCA.

**Discussion**

**Significant metabolites as PD biomarkers**

As summarized in Table 2, most of the significant metabolomic parameters presented different concentration levels in PD and HC subjects, following the expectations of the current knowledge regarding the metabolic changes in PD. For instance, a decreased level of acyl-carnitines has been found in possible association to primary decrement of mitochondrial β-oxidation and has been identified as a possible biomarker for PD [32]. Similarly, increased levels of trimethylamine N-oxide have been observed in PD patients. This amine oxide can cross the blood–brain barrier promoting cellular α-synuclein aggregations, neuroinflammation, mitochondrial dysfunction, and neuronal senescence [33]. As for amino acids, results are more controversial. For instance, our results confirm that no difference of glutamate concentration has to be expected in PD compared to HC [34], although an higher glutamate concentration has been indeed reported in PD patients [35, 36]. More interestingly, the importance of threonine as a possible PD biomarker is confirmed also in other studies [37]. Similarly, high levels of putrescine and ceramides in the blood of PD patients have also been observed [38, 39]. Polyamines, such as putrescine, cadaverine, spermidine and spermine, are involved in many vital processes, including cell proliferation and differentiation, gene transcription and translation, modulation of ion channels and receptors, and can promote the aggregation and fibrillation of α-synuclein [38]. Ceramides play an essential role not only in shaping cell membranes, but also in regulating cellular processes of vital importance in PD. This leads to the observation, supported and confirmed also in other studies [39], of elevated Ceramide levels in PD patients.

In general, the finding that cholesteryl esters, sphingomyelins, fatty acids, dihexosylceramides, hexosylceramides, ceramides, phosphatidylcholines, lysophosphatidylcholines, diglycerides and triglycerides have a high impact in the discrimination between PD and HC indicates a general alteration of lipid metabolism in PD [40, 41], supporting the hypothesis of PD as a lipidopathy [42]. Finally, the increase of the triglycerides levels observed in this study disagrees with the literature, which shows a reduction or no differences in PD patients compared to HC [40]. However, our result is in line with a post-mortem lipidomic study showing an increase of triglycerides in the CSF of PD patients [43]. The ethnical and demographic characteristics of the subjects might be a possible explanation for the observed discrepancy [41].

**Glycine, threonine, and serine metabolism correlates with age only in PD patients**

A striking result of our study is that metabolites related to the glycine, threonine and serine metabolism exhibit a correlation with age in PD patients, but not in healthy subjects. It is well known that, in the production process of ATP from ADP, the creatine generated from threonine provides the necessary phosphate groups. As for PD, the relationship between glycine, serine and threonine metabolism has been intensively proved at the onset of α-synuclein aggregation, when glycine, serine and threonine metabolism exhibit a remarkable age-dependence only in PD patients [44]. However, a direct observation of the age dependency of this metabolic pathway in PD has never been reported. The fact that age-dependent mechanisms may occur in PD is corroborated by the recently observed age-dependent neuromelanin production in PD [45]. Although there is no direct association between neuromelanin, threonine, glycine, and serotonin, this finding shows that age dependent mechanisms must be expected in PD. The fact that glycine, serine and threonine metabolism have a remarkable age-dependence only in PD patients suggests that this metabolic pathway might be associated with the neurodegenerative process typical of PD. Choline is the metabolic product of glycine, serine and threonine metabolism and exhibits a striking age dependence only in PD subjects, as mentioned above. Abnormal choline transport and metabolism have been implicated in several neurodegenerative disorders. It is an essential nutrient for all cells because it plays a critical role in the synthesis of the neurotransmitter acetylcholine. Its
deficiency affects the expression of genes involved in cell proliferation, differentiation, and apoptosis, and it has been associated with liver dysfunction and cancer [46].

Indirect evidence of the association of glycine metabolism to age is supported by a series of independent results. By comparing young and old human fibroblasts it was found that epigenetic downregulation of the glycine-C-acetyltransferase (GCAT) and serine hydroxymethyltransferase 2 (SHMT2) genes involved in mitochondrial glycine synthesis correspond to the aging-related loss of

---

**Fig. 2** The OPLS model with 3 orthogonal and 1 predictive components can distinguish between PD and HC with an AUC in the range (0.97, 1.0) at a 95% confidence level (A). The principal component analysis applied to the significant metabolic parameters with VIP > 1 identifies 5 components expressing up to 80% of the total variance. In particular, f0,1,4 does not exhibit any age dependence (B), f2 exhibits a age correlation only for PD patients (C) and f3 exhibits a age correlation only for HC subjects (D). Sphingomyelin (E), Choline (F) and Hexadecanoyl-carnitine (G) are among the main contributions to the three principal components.
Fig. 3  Pathway analysis. The box plots of 8 significant metabolomic parameters validated in OPLS reveal a difference of the concentration between PD and HC subjects (A). An enrichment analysis verifies that the selected parameters can be associated with the biosynthesis of unsaturated fatty acids, the tryptophan metabolism and the glycine, serine and threonine metabolism (B). We verified that the metabolites composing the first and the third pathway are correlated with age only in HG and PD subjects, respectively.
cellular respiration. Interestingly, the phenotype of aged cells is restored back to young cells by adding glycine to the culture media [47, 48]. The role of serine synthesis in age-related diseases has been intensively studied. It has been shown that serine can directly affect lifespan through metabolic regulation [49].

Our results also open new possible exploration pathways in the relationship between PD and other chronic neurodegenerative diseases, such as Alzheimer’s Disease (AD). Glycine, serine, and threonine metabolism is in fact one of the six metabolic pathways that distinguish HC from AD patients [50]. Furthermore, metabolomic analysis has recently shown that the cognitive impairment due to post-traumatic brain injuries is associated with aberrations in glycine, serine and threonine metabolism [51]. When it comes to age dependency, preclinical studies may provide indirect evidence. A recent metabolomics analysis was performed on triple transgenic AD (3xTg-AD) 2- and 6-month-old mice. Relevant metabolites were identified following a statistical analysis like the one presented in this paper. Glycine, serine and threonine metabolism appeared as a significant metabolic pathway in the 6-month-old mice but not in the 2-month-old mice [52]. An imbalance between excitability (aspartate and glutamine) and inhibition (GABA and Glycine) may be a signature of AD. While this finding may suggest a dependence of glycine, serine and threonine metabolism on the progression of the disease, it is not in direct relationship with age.

More suggestive implications of our results in the intimate connections between AD and PD may be found with a deeper understanding of the spleen to brain connection [53]. The splenic nerve connects to the vagus nerve, which is connected to the brain stem. In a metabolomic study on AD mice models, it has been observed that impaired glycine, serine and threonine pathways were correlated with the increase in spleen size of AD mice at 6 months of age and in control mice at an age of 24 months. More interestingly, the age dependence of glycine, serine and threonine pathways does not exhibit any difference between healthy controls and AD after 24 months, therefore suggesting the absence of any age dependency at a later stage of the disease [54]. Following this observation, although our results enhance for the first time to our knowledge a clear age-dependence of the glycine, serine and threonine metabolic pathway in PD, it will be interesting to understand the strength of this effect at later stages of the disease.

**Biosynthesis of fatty acids correlates with age only in healthy subjects**

As mentioned above, the metabolites identified in this study support the strict relationship between PD and lipids. Alterations in the biosynthesis of fatty acids are not only indicative of a mitochondrial disfunction, but also of possible processes of mitophagy and apoptosis implied by the development of PD [55]. It has been observed how the integration of fatty acids omega-3 have a neuroprotective action in a model of hemiparkinsonism [56]. The effect of age on the biosynthesis of unsaturated fatty acids in the HC group is clearly connected with the emerging role of lipid metabolism [57]. For instance, age correlation of lipids and fatty acids has been found in the analysis of plasma samples from a cohort of 269 individuals [58]. The observation of a different age correlation between HC and PD agrees with other findings. By way of example, aldosterone, pantothenic acid, and N-acetyl-methionine were associated with age in HC; however, only 1 metabolite FFA 12:0 showed association with age in PD [59]. Therefore, the absence of correlation in PD patients may indicate an already compromised metabolism and needs further investigation.

**Tryptophan metabolism characterizes PD but does not correlate with age**

The role of tryptophan in PD is well-documented. Particularly kynurenine, a key intermediate in the breakdown of tryptophan and formation of nicotinamide adenine dinucleotide (NAD+) via the kynurenine pathway (KP), is involved in a variety of physiopathological processes and diseases—including cancer, autoimmune diseases, inflammatory diseases, neurologic diseases and psychiatric disorders [60]. KP metabolites, such as quinolinic acid, cause neurotoxicity and consequently neuronal apoptosis and neurodegeneration, while others, such as the kynurenic acid, act as neuroprotectant. Furthermore, excess levels of quinolinic acid lead to the formation of metabolite assemblies that causes α-synuclein aggregation, with consequent neuronal toxicity and PD [61]. Metabolites associated with tryptophan metabolism also modulate inflammation, regulate energy homeostasis and control mental health [62]. PD patients show lower kynurenic acid and higher quinolinic acid levels compared to HC, especially in advanced stages of the disease [63]. When it comes to other neurodegenerative diseases, tryptophan metabolism has been found in significant relationship with both AD and Mild Cognitive
Impairment (MCI) progression [64]. Contrary to previous studies exhibiting a robust association of tryptophan metabolism with aging [65], we did not observe any significant age dependency.

**Conclusion**

In conclusion, the targeted analysis of the blood metabolome proposed in this paper allowed to find specific age-related metabolites and metabolic pathways. The predictive OPLS model developed in this paper has an excellent discrimination power between PD and HC and offers a promising set of blood biomarkers for a personalized age-dependent approach to the early PD diagnosis.

**Abbreviations**

ADP: Adenosine diphosphate; ATP: Adenosine triphosphate; AUC: Area under the curve; CDR: Clinical dementia rating; CSF: Cerebrospinal fluid; HC: Healthy control; IRB: Institutional Review Board; KEGG: Kyoto Encyclopedia of Genes and Genomes; KP: Kynurenine pathway; MDS: Movements Disorder Society; MDS-UPDRS: MDS-revised Unified Parkinson's Disease Rating Scale; MMSE: Mini Mental State Examination; NAD: Nicotinamide adenine dinucleotide; OPLS: Ordered projection to latent structures; PD: Parkinson’s Disease; PLS-DA: Partial least squares-discriminant analysis; ROC: Receiver operating characteristics; TCA: Tricarboxylic acid cycle; VIP: Variable influence on projection.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s13578-022-00831-5.

**Acknowledgements**

We thank Claudio Caimi and the Hewlett Packard Enterprise (HPE) team for the support in the operation of the Ezmeral platform.

**Author contributions**

ND and AD designed the research and wrote the manuscript; ND designed the statistical analysis concept and developed the statistical analysis software; ND, EA, VB and QX performed the data analysis; MC was responsible of IT issues and platform integration; AA and AD were responsible of the analysis software; ND, EA, VB and QX performed the data analysis; MC was responsible of IT issues and platform integration; AA and AD were responsible of the analysis software.

**Funding**

The authors acknowledge the support of the Gatekeeper 1st open call, Grant number 857223 and of the MAECI Great Relevance 2019 contributions Italy-China (Grant No. PGR00846).

**Availability of data and materials**

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request. In addition, the datasets and the analysis software will be made available in the digital healthcare platform prepared by the GATEKEEPER consortium.

**Declarations**

**Ethics approval and consent to participate**

The Institutional Review Board (IRB) of the University of Molise reviewed and approved the study (IRB Prot. n. 17/2020).

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1. Huazhong University of Science and Technology, Wuhan, China. 2. Department of Medical Physics and Engineering, Istituto Neurologico Mediterraneo NEU-ROMED I.R.C.C.S., Pozzilli, Italy. 3. Centre for Research and Training in Medicine of Aging, Department of Medicine and Health Sciences “V. Tiberio”, University of Molise, Campobasso, Italy. 4. NIM Competence Center for Digital Healthcare GmbH, Berlin, Germany. 5. University of Science and Technology of China, Hefei, China.

**Received:** 13 January 2022 **Accepted:** 8 June 2022

**Published online:** 06 July 2022

**References**

1. Ray Dorsey E. Global, regional, and national burden of Parkinson’s disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17:939–53.
2. Spillantini MG, Goedert M. Neurodegeneration and the ordered assembly of a-synuclein. Cell Tissue Res. 2018;373:137–48.
3. Bloem B, Okun M, Klein C. Parkinson’s disease. Lancet. 2021;397:2284–303.
4. Shao Y, Le W. Recent advances and perspectives of metabolomics-based investigations in Parkinson’s disease. Mol Neurodegener. 2019;14:3.
5. Abdullah R, Basak I, Patil K, Alves G, Larsen J, Möller S. Parkinson’s disease and age: the obvious but largely unexplored link. Exp Gerontol. 2015;63:33–8.
6. Davies K, Bohic S, Carmona A, Ortega R, Cottam V, Hare D, Finberg J, Reyes D, Halliday G, Mercer J. Double Copper pathology in vulnerable brain regions in Parkinson’s disease. Neurobiol Aging. 2014;35:858–66.
7. Esteves A, Svedlow R, Cardoso S. LRRK2, a puzzling protein: insights into Parkinson’s disease pathogenesis. Exp Neurol. 2014;261:206–16.
8. Santini E, Heiman M, Greengard P, Valjent E, Fisone G. Inhibition of mTOR signaling in Parkinson’s disease prevents L-DOPA-induced dyskinesia. Sci Signal. 2009;2:r3.
9. Nystrom T, Yang J, Molin M. Peroxiredoxins, gerontogenes linking aging to genome instability and cancer. Genes Dev. 2012;26:2501–8.
10. Shao Y, Le W. Recent advances and perspectives of metabolomics-based investigations in Parkinson’s disease. Mol Neurodegeneration. 2019;14:3.
11. Kondoh H, Kameda M, Yanagida M. Whole blood metabolomics in aging research. Int J Mol Sci. 2021;22:175.
12. Hallett P, Engelande S, Isacson O. Lipid and immune abnormalities causing age-dependent neurodegeneration and Parkinson’s disease. J Neuroinflammation. 2019;16:153.
13. Sinclair E. Metabolomics of sebum reveals lipid dysregulation in Parkinson’s disease. Nat Commun. 2021;12:1592.
14. Mattsson N. CSF biomarkers in neurodegenerative diseases. Clin Chem Lab Med. 2011;49:345–52.
15. Engelande S, Maesrauc B, De Deyn P. Amino acids and biogenic amines in cerebrospinal fluid of patients with Parkinson’s disease. Neuropsychopharmacol Res. 2003;28:1145–50.
16. Hong Z, DJ-1 and a-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease. Brain. 2010;133:713–26.
17. Postuma R, Berg D, Stern M. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2015;30(12):1591–601.
18. Goetz C, Tilley B, Shaffman S. Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS). scale presentation and clinimetric testing results. Mov Disord. 2008;23(15):2129–70.
19. Galindo-Prieto B, Eriksson L, Trygg J. Variable influence on projection (VIP) for OPLS models and its applicability in multivariate time series analysis. Chemom Intell Lab Syst. 2015;146:297–304.
20. Lee L, Lioni C, Jemain A. Partial least squares-discriminant analysis (PLS-DA) for classification of high-dimensional (HD) data: a review
of contemporary practice strategies and knowledge gaps. Analyst. 2018;143:3526–39.

21. Trygg J, Wold S. Orthogonal projections to latent structures (O-PLS). J Chemom. 2002;16:119–28.

22. Triba M, Le Moyec J, AmattheuI Re, Goossens C, Bouchemail N, Nahon P, Rutslegend D, Savarina P. PLS/OLPS models in metabolomics: the impact of permutation of dataset rows on the K-fold cross-validation quality parameters. Mol BioSyst. 2015;11:13–9.

23. Huang L, Fuchins H, Kawahana N, Narukawa Y, Hada N, Kiuchi F. Application of a new method, orthogonal projection to latent structure (OPLS) combined with principal component analysis (PCA), to screening of prostaglandin E2 production inhibitory flavonoids in Scutellaria Root. J Nat Med. 2016;70:731–9.

24. Gao X, Starmer J, Martin E. A multiple testing correction method for genetic association studies using correlated single nucleotide polymorphisms. Genet Epidemiol. 2008;32:361–9.

25. Öthrac F, Soussean M, Misonofoo J-A, Garcia C, Vanderlinden B, Buvat I. O-PLS/OLPS/PLS models combined with principal component analysis (PCA), to screening of Parkinson’s disease pathogenesis. Nature Commun. 2019;10:973.

26. Johnson R, Nelson G, Troyer J, Lautenberger J, Kessing B, Wrinkler C, Rutledge D, Savarina P. PLS/OPLS models in metabolomics: the impact of contemporary practice strategies and knowledge gaps. Analyst. 2016;141:191–8.

27. Figura M, Kuśmierska K, Bucior E, Szlufik S, Koziorowski D, Jamrozik Z, Janik P. Serum amino acid profile in patients with Parkinson’s disease. J Neurol Sci. 1996;141(1):39–44.

28. D’Ascenzo F, Iver M, Naravanasamv A, Siva K, Vellingiri B. Kynurenic acid in the plasma of Parkinson’s disease patients. Neurosci Letters. 2018;679:129–34.

29. Yamashiro K, Hattori N. Decreased long-chain acylcarnitines from insufficient citrulline production in Parkinson’s disease. Neurosci Lett. 1998;246:111–5.

30. Makletsova M, Syatkin S, Poleshchuk V, Urazgildeeva G, Chigaleychik L, Fukuhara T, Koinuma T, Imamichi Y, Nagumo M, Furuya N, Noini S, Amo T, Yamashiro K, Hattori N. Decreased long-chain acylcarnitines from insufficient β-oxidation as potential early diagnostic markers for Parkinson’s disease. Sci Rep. 2017;7(1):7328.

31. Szú-Ju C, Chin-hua H, Han-Chun K, Cheh-Chang C, Wei-Kai W, Jyh-Ming L, Ming-Shiang W, Chin-Hsien L. The gut metabolite trimethylamine N-oxide is associated with Parkinson’s disease severity and progression. Mov Disord. 2020;35(11):2115.

32. Mally J, Szalai G, Stone T. Changes in the concentration of amino acids in serum and cerebrospinal fluid of patients with Parkinson’s disease. J Neurol Sci. 1997;152(1–2):159–62.

33. Iwasaki Y, Ikeda K, Shiojima T, Kinoshita M. Increased plasma concentrations of aspartate, glutamate and glycine in Parkinson’s disease. Neurosci Lett. 1997;242(2):175–7.

34. Jiménez-Jiménez F, Molina J, Vargas C, Gómez P, Navarro J, Benito-Leon J. Neurotransmitter amino acids in cerebrospinal fluid of patients with Parkinson’s disease. J Neurol Sci. 1996;141(1):39–44.

35. Saiki S, Hatano T, Fujimaki M, Ishikawa K, Mori A, Oji Y, Okuzumi A, Oji L, Ono T, Kato H, Kitadokoro T. The role of lipids in aging, lifespan regulation, and age-related disease. Aging Cell. 2019;18(1):27.

36. Yamashiro K, Hattori N. Decreased long-chain acylcarnitines from insufficient citrulline production in Parkinson’s disease. Neurosci Lett. 1998;246:111–5.

37. Johnson R, Nelson G, Troyer J, Lautenberger J, Kessing B, Wrinkler C, Rutledge D, Savarina P. PLS/OPLS models in metabolomics: the impact of contemporary practice strategies and knowledge gaps. Analyst. 2016;141:191–8.

38. Müller V, Yuan Z, Bakuovic M. Choline transport for phospholipid synthesis. Exp Biol Med. 2006;231(5):490–504.

39. Hashizume O, Ohnishi S, Mito T, Shimizu A, Ishikawa K, Nakada K, Soda M, Mano H, Togayachi S, Miyoshi H, Oikawa K, Hayashi Y. Epigenetic regulation of the nuclear-coded GCAT and SHMT2 genes confers human age-associated mitochondrial respiration defects. Sci Rep. 2015;5:10434.

40. Mano H, Togayachi S, Miyoshi H, Oikawa K, Hayashi Y. Epigenetic regulation of the nuclear-coded GCAT and SHMT2 genes confers human age-associated mitochondrial respiration defects. Sci Rep. 2015;5:10434.

41. Xicoy H, Wieringa B, Martens G. The role of lipids in Parkinson’s disease. Nat Med. 2016;70:731–9.

42. Fanning S, Selkoe D, Dettmer U. Parkinson’s disease: proteinopathy or lipidopathy? NPJ Parkinson’s Dis. 2020;3:1–9.

43. Fernández-Ingoyen J, Cartas-Dejudo P, Iruarrizaga-Lejarreta M, Santamaria E. Alteration in the cerebrospinal fluid lipidome in Parkinson’s disease: a post-mortem pilot study. Biomedicines. 2021;9(5):491.

44. Graham SF, Rey NL, Yilmaz A, Kumar P, Maddens M, Bakovic M. Choline transport for phospholipid synthesis. Exp Biol Med. 2006;231(5):490–504.

45. Michel V, Yuan Z, Ramsurub S, Bakovic M. Choline transport for phospholipid synthesis. Exp Biol Med. 2006;231(5):490–504.

46. Michel V, Yuan Z, Ramsurub S, Bakovic M. Choline transport for phospholipid synthesis. Exp Biol Med. 2006;231(5):490–504.

47. Johnson A, Stolzing A. The role of lipid metabolism in aging, lifespan regulation, and age-related disease. Aging Cell. 2019;18(6):e13048.

48. Lawton K, Berger A, Mitchell M, Milgram K, Evans A, Guo L. Analysis of the nuclear-coded GCAT and SHMT2 genes confers human age-associated mitochondrial respiration defects. Sci Rep. 2015;5:10434.

49. Lawton K, Berger A, Mitchell M, Milgram K, Evans A, Guo L. Analysis of the nuclear-coded GCAT and SHMT2 genes confers human age-associated mitochondrial respiration defects. Sci Rep. 2015;5:10434.

50. Michel V, Yuan Z, Ramsurub S, Bakovic M. Choline transport for phospholipid synthesis. Exp Biol Med. 2006;231(5):490–504.

51. Michel V, Yuan Z, Ramsurub S, Bakovic M. Choline transport for phospholipid synthesis. Exp Biol Med. 2006;231(5):490–504.

52. Zhao Y, Chen H, Iqbal J, Liu X, Zhang H, Xiao S, Jin N, Yao F, Shen L. Targeted metabolomics study of early pathological features in hippocampus of trile aged Alzheimer’s disease male mice. J Neurosci Res. 2021;99:927–46.

53. Carnevale D. A cholinergic-sympathetic pathway primes immunity in hypertension and mediates brain-to-spleen communication. Nat Commun. 2016;7:13035.

54. Hunsberger H, Greenwood B, Tolstikov V, Nairn N, Kiebish M, Denny CA. Divergence in the metabolome between natural aging and Alzheimer’s disease. Sci Rep. 2020;10:12171.

55. Tyurina Y, Polimova A, Maciel E, Tyurin V, Kapralova V, Vininina D, Vikulina A, Domingues M, McCoy J, Sanders L. LC/MS analysis of cardioliopins in substantia nigra and plasma of rotenone-treated rats: implication for mitochondrial dysfunction. Free Radic Res. 2015;49:681–91.

56. Hunsberger H, Greenwood B, Tolstikov V, Nairn N, Kiebish M, Denny CA. Divergence in the metabolome between natural aging and Alzheimer’s disease. Sci Rep. 2020;10:12171.

57. Figura M, Kuśmierska K, Bucior E, Szlufik S, Koziorowski D, Jamrozik Z, Janik P. Serum amino acid profile in patients with Parkinson’s disease. PLoS ONE. 2018;13(1):e0191670.

58. Figura M, Kuśmierska K, Bucior E, Szlufik S, Koziorowski D, Jamrozik Z, Janik P. Serum amino acid profile in patients with Parkinson’s disease. PLoS ONE. 2018;13(1):e0191670.

59. Figura M, Kuśmierska K, Bucior E, Szlufik S, Koziorowski D, Jamrozik Z, Janik P. Serum amino acid profile in patients with Parkinson’s disease. PLoS ONE. 2018;13(1):e0191670.

60. Figura M, Kuśmierska K, Bucior E, Szlufik S, Koziorowski D, Jamrozik Z, Janik P. Serum amino acid profile in patients with Parkinson’s disease. PLoS ONE. 2018;13(1):e0191670.

61. Figura M, Kuśmierska K, Bucior E, Szlufik S, Koziorowski D, Jamrozik Z, Janik P. Serum amino acid profile in patients with Parkinson’s disease. PLoS ONE. 2018;13(1):e0191670.
biomarkers and identifying metabolic mechanisms in aging and Alzheimer’s disease. Front Cell Dev Biol. 2021;9:335.

65. Sorgdrager-Freek JH, Naudé Petrus JW, Kema Ido P, Nollen EA, Deyn Peter PD. Tryptophan metabolism in inflamming: from biomarker to therapeutic target. Front Immunol. 2019;10:2565.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.